Abstract
Interleukin 17 is a proinflammatory cytokine playing important role in the pathogenesis of spondyloarthritis and other associated diseases (psoriasis, Crohn disease etc.). Inhibition of IL-17 has a pronounced anti-inflammatory effect presenting with reduction of psoriatic lesions, decreasing of activity of psoriatic arthritis, ankylosing spondylitis and Crohn disease.
Currently, three monoclonal antibodies are registered for treatment of psoriasis - ustekinumab (human monoclonal antibody against IL-12/23 with indirect inhibition of IL-17), secukinumab (human monoclonal antibody against IL-17) and ixekizumab (humanized monoclonal antibody against proti IL-17). Secukinumab is registered in ankylosing spondylitis and psoriatic arthritis, ustekinumab in psoriatic arthritis.
Efficacy of anti-IL 17 in psoriasis is higher than TNFα inhibitors but in psoriatic arthritis the efficacy is comparable or lower.